Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of the GLP-1 hormone in the body [1]. In comparison, insulin is a hormone produced by the pancreas that regulates blood sugar levels [2].

One key difference between Ozempic and insulin is how they work. Ozempic stimulates the release of insulin from the pancreas and promotes glucose uptake in the muscles and fat, while also slowing gastric emptying to prevent a rapid increase in blood sugar levels [3]. Insulin, on the other hand, directly lowers blood sugar levels by facilitating the entry of glucose into cells [4].

Studies have shown that Ozempic can lead to significant weight loss and improvements in blood sugar control, with an estimated 1.5- to 2-fold increase in insulin sensitivity [5]. In contrast, insulin therapy can lead to weight gain due to increased glucose storage as glycogen and fat [6].

According to DrugPatentWatch.com, the patent for Ozempic is set to expire in 2030, which may lead to increased generic competition and potential price reductions [7].

In comparison to insulin, Ozempic may be beneficial for patients who require a more gradual increase in insulin sensitivity and weight loss, particularly those with obesity or pre-diabetes [8]. However, it's essential to consult a healthcare professional before starting any new medication, as both Ozempic and insulin may cause side effects and interact with other medications.

Sources:
[1] https://www.drugs.com/ozempic.html
[2] https://www.niddk.nih.gov/health-information/diabetes/insulin
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765337/
[4] https://www.ncbi.nlm.nih.gov/pubmed/16865359
[5] https://www.sciencedaily.com/releases/2016/06/160603144145.htm
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754197/
[7] https://www.drugpatentwatch.com/patents/US10941919
[8] https://www.nature.com/articles/nrendo2018125